KYTX Shareholders Are Encouraged By The Schall Law Firm To Participate In The Securities Fraud Investigation Into Kyverna Therapeutics IncAccesswire • 07/08/24
KYTX Investors Are Urged By The Schall Law Firm To Be Part Of The Securities Fraud Inquiry Into Kyverna Therapeutics IncAccesswire • 07/07/24
KYTX Stakeholders Are Encouraged By The Schall Law Firm To Participate In The Securities Deception Investigation Into Kyverna Therapeutics IncAccesswire • 07/06/24
KYTX Shareholders Are Invited By The Schall Law Firm To Join The Securities Fraud Probe Into Kyverna Therapeutics IncAccesswire • 07/03/24
The Schall Law Firm Is Conducting A Securities Fraud Investigation Into Kyverna Therapeutics Inc And Invites KYTX Shareholders To ParticipateAccesswire • 07/02/24
Kyverna Therapeutics Inc And KYTX Stock Proprietors Are Welcomed To Engage In A Securities Fraud Examination Performed By The Schall Law FirmAccesswire • 07/01/24
Kyverna Therapeutics Inc And KYTX Stock Possessors Are Requested To Be Part Of A Securities Fraud Inquiry Carried Out By The Schall Law FirmAccesswire • 06/30/24
Kyverna Therapeutics Inc And KYTX Stock Holders Are Invited To Join A Securities Fraud Probe Conducted By The Schall Law FirmAccesswire • 06/29/24
Kyverna Therapeutics Inc And KYTX Shareholders Are Invited To Be Involved In A Securities Fraud Probe Conducted By The Schall Law FirmAccesswire • 06/28/24
The Schall Law Firm Is Undertaking A Securities Fraud Probe Into Kyverna Therapeutics Inc And Encourages KYTX Shareholders To JoinAccesswire • 06/27/24
Kyverna Therapeutics Inc And KYTX Stock Owners Are Encouraged To Participate In A Securities Fraud Investigation Led By The Schall Law FirmAccesswire • 06/26/24
KYTX Shareholders Have The Opportunity To Participate In The Securities Fraud Investigation Of Kyverna Therapeutics Inc Led By The Schall Law FirmAccesswire • 06/23/24
The Schall Law Firm Is Conducting A Securities Fraud Probe Into Kyverna Therapeutics Inc And KYTX Shareholders Are Invited To Be InvolvedAccesswire • 06/22/24
KYTX Shareholders Can Join The Securities Fraud Investigation Of Kyverna Therapeutics Inc Conducted By The Schall Law FirmAccesswire • 06/21/24
Shareholders Of KYTX Have The Opportunity To Participate In The Securities Fraud Scrutiny Of Kyverna Therapeutics Inc Led By The Schall Law FirmAccesswire • 06/20/24
Kyverna's KYV-101 Receives U.S. FDA IND Clearance for Treatment of Patients With Treatment-Refractory Stiff-Person Syndrome in the KYSA-8 Phase 2 TrialPRNewsWire • 06/20/24
Investors Of KYTX Can Join The Securities Fraud Investigation Of Kyverna Therapeutics Inc Conducted By The Schall Law FirmAccesswire • 06/19/24
KYTX Investors Can Join The Securities Fraud Investigation Of Kyverna Therapeutics Inc By Schall Law FirmAccesswire • 06/18/24
First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patient With Severe Stiff-Person Syndrome Published in Proceedings of the National Academy of Sciences (PNAS)PRNewsWire • 06/17/24
Investors In KYTX Have The Chance To Participate In The Securities Fraud Probe Against Kyverna Therapeutics, Inc. With The Schall Law FirmAccesswire • 06/17/24
KYTX Investors Have Opportunity to Join Kyverna Therapeutics, Inc. Securities Fraud Investigation with the Schall Law FirmBusiness Wire • 06/14/24
Kyverna Therapeutics and National Institutes of Health Co-Author Seminal Review on Cell Therapy for Autoimmunity in Nature Reviews ImmunologyPRNewsWire • 06/10/24
Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial ResultsPRNewsWire • 05/14/24
Kyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune DiseasesPRNewsWire • 04/11/24
First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in MedPRNewsWire • 03/29/24
